A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care

Trial Profile

A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs HTL 18318 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Heptares Therapeutics
  • Most Recent Events

    • 26 Jul 2018 Last checked against the ClinicalTrials.gov record.
    • 19 Jul 2018 Status changed from recruiting to completed.
    • 09 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top